1. Blumenthal D. Doctors and drug companies. N Engl J Med. 2004;351:1885–90.
2. Coleman DL, Kazdin AE, Miller LA, Morrow JS, Udelsman R. Guidelines for interactions between clinical faculty and the pharmaceutical industry: one medical school’s approach. Acad Med. 2006;81:154–60.
3. HUP/CPUP policy #1-07-10 “Guidelines for Interactions between Healthcare Professionals and Industry": Hospital of the University of Pennsylvania Clinical Practices of the University of Pennsylvania; 2006. http://www.uphs.upenn.edu/cep/resources/PhARMA%202-202006%20prof-industry.pdf . Accessed on February 20, 2008.
4. HUP/CPUP policy #1-12-41 “Pharmaceutical Company Representative Activity": Hospital of the University of Pennsylvania Clinical Practices of the University of Pennsylvania; 2007. http://www.uphs.upenn.edu/cep/resources/1_12_41%20pharma%20policy.pdf . Accessed on February 20, 2008.
5. Policy and Guidelines for Interactions between the Stanford University School of Medicine, the Stanford Hospital and Clinics, and Lucile Packard Children’s Hospital with the Pharmaceutical, Biotech, Medial Device, and Hospital and Research Equipment and Supplies Industries (“Industry”): Stanford Hospital and Clinics; 2006. http://med.stanford.edu/coi/siip/policy.html Accessed on February 20, 2008.